Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2026 · third_quarter · Medicare/Medicaid
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
2026 · third_quarter · Medicare/Medicaid
Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Pharmacy
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
H.R.7118, Genomic Answers for Childrens Health Act H.R.1414, Camerons Law H.R.1492/S.832, EPIC Act S.3019, No Big Blockbuster Bailouts Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Pharmacy
prescription drug international reference pricing, serial patent litigation reform, Patent Eligibility Restoration Act (S.1546, H.R. 3152), EPIC Act (H.R. 1492 / S. 832); Medicare drug price negotiation delay periods; prescription drug prices, direct to consumer drug sales, Surgeon General nomination, No Big Blockbuster Bailouts Act (S.3019); EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Defense Production Act; price gouging, FDA Commissioners Priority Review Voucher; enhanced premium tax credits, S. 1040 Drug Competition Enhancement Act; S. 1095 Stop STALLING Act; S. 1096 Preserve Access to Affordable Generics and Biosimilars Act; S.2276/H.R.3269 ETHIC Act; drug pricing, S.3019 No Big Blockbuster Bailouts Act, Medicare drug price negotiation program; Medicare drug price negotiation delay periods and exemptions; drug prices, No Big Blockbuster Bailouts Act; Medicare drug price negotiation delay periods and exemptions; , End Price Gouging for Medications Act; prescription drug international reference pricing, EPIC Act (H.R. 1492 / S. 832), MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions; drug prices, Medicare drug price negotiation program improvement and expansion; negotiation delay periods and exemptions.
Client expense: $73,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE